CAPTRUST Financial Advisors
INMB icon

CAPTRUST Financial Advisors’s INmune Bio INMB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-269
Closed -$2K – 3025
2022
Q2 		$2K Hold
269
– – ﹤0.01% 4471
2022
Q1 		$2K Hold
269
– – ﹤0.01% 4493
2021
Q4 		$3K Sell
269
-131
-33% -$1.94K ﹤0.01% 4278
2021
Q3 		$8K Hold
400
– – ﹤0.01% 3735
2021
Q2 		$7K Buy
+400
New +$5.39K ﹤0.01% 3707

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CAPTRUST Financial Advisors's INMB Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of INmune Bio (INMB) in Q3 2022, closing a stake of 269 shares — an estimated $2K sold.

CAPTRUST Financial Advisors first reported a position in INMB in Q2 2021 and held it in 5 quarters. The position peaked at $8K in Q3 2021. 33 funds tracked by Wall St. Rank hold INMB as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining INmune Bio position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 269 INmune Bio shares in Q3 2022, an estimated $2K.
  • CAPTRUST Financial Advisors first reported a position in INmune Bio in Q2 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's INmune Bio position peaked at $8K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held INmune Bio as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.